- Global Pharma News & Resources

High Use of Digital PCR and Real-time PCR in Genetical and Cancerous Diseases Boosted the Market: Meticulous Research

Meticulous Research® – leading global market research company has been researching on a market Global Digital PCR and Real-time PCR (qPCR) Market by Product (Instrument, Reagent, Consumables), Technology (qPCR, dPCR), Application (Oncology, Pathogen Detection, Research, Forensic), End User (Pharma, Academic, Hospitals, CRO). It is also going to provide the forecast till 2024 in its market study.

Increasing incidence & prevalence of genetic & infectious diseases, technological advancement in PCR, rising number of CROs, forensic laboratories, and other research laboratories are driving the adoption of dPCR and qPCR market. Moreover, emerging opportunities from Asian countries and transition from plant to genome based drug discovery will provide high opportunities for this market during forecast period. On the other hand, technical limitations associated with PCR and high cost of PCR devices are expected to restrict the faster growth of the market.

Download Complete Free Sample PDF Copy NOW:

Rising Number of Genetic Diseases is Propelling the Growth of Market

Globally, about 3-6% of babies are born with genetic defect each year. This is mainly attributed to ethnic diversity, high rate of consanguineous marriage, relative lack of genetic or diagnostic sources, and lack of awareness about the significance of genetic disorders. According to the Cancer Research U.K., there were 14.1 million new cases of cancers globally in 2012 and this number is expected to increase 68% by 2030. Moreover, number of new cases of acute Hepatitis A viral infection was 0.54 per 100,000 population in 2010 and increased to 0.62 in 2016 in the U.S. Such growing number of infectious diseases is expected to propel the use of PCR technologies for accurate detection.

Clinical Application Segment Commanded the Largest Share in the Global Digital PCR and Real-time PCR Market

Early detection of cancer is one of the main targets among clinical applications of PCRs. As per the data from Centers for Disease Control and Prevention (CDC), the number of deaths due to cancers in the U.S. was 575,000 in 2010 and expected to increase to 630,000 in 2020. This is mainly due to morbid lifestyle, heredity, and others. Thus, increasing number of cancer cases and related deaths found to be one of the main reasons for largest share of clinical application in the global market.

Check complete table of contents with list of table and figures:

North America: Largest Regional Market 

North America is expected to be the largest regional market, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa. The higher adoption of advanced technologies, well established healthcare research and diagnostic industries, increasing funding for qPCR and dPCR technologies, growing incidence & prevalence of infectious and genetic diseases, continuous reduction in gene sequencing cost, and presence of key players in the region are responsible for largest share of North American market. However, Asia Pacific region is expected to grow at a fastest CAGR due to rapidly developing economies, growing aging population coupled with rising incidence of genetic diseases, rise in government support for life science research, growing research & clinical trial outsourcing from the region, and increasing number of CROs.

Have Any Query? Ask Our Experts Here:

Major Players in the Digital PCR and Real-time PCR (qPCR) Market

Vendors are moving towards launching of new products along with technological advancement for effective drug discovery & development and accurate diagnosis & treatment. For instance, in 2018, Bio-Rad Laboratories, Inc. launched iQ-Check Vibrio Real-Time PCR Detection Kit that can detect vibriosis namely V. cholerae, V. parahaemolyticus, and V. vulnificus species. The entire detection process takes only 11 hours with the help of this kit. Moreover, F. Hoffmann-La Roche Ltd. (Switzerland) launched cobas Liat PCR System with four assays to detect Clostridium difficile. This provides rapid and definitive results under 20 minutes.

The key players operating in dPCR and qPCR market are Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories Inc. (U.S.), QIAGEN N.V. (Netherlands), Takara Bio Inc. (Japan), bioMérieux S.A. (France), Agilent Technologies, Inc. (U.S.), Fluidigm Corporation (U.S.), Abbott Laboratories (U.S.), Merck KGaA (Germany), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Promega Corporation (U.S.), Meridian Bioscience, Inc. (U.S.), and Analytik Jena AG (Germany).

Make an inquiry for purchasing this report:

Contact Us:
Meticulous Research®
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn-

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at

Editor Details

Last Updated: 21-Feb-2020